Thursday, July 24, 2025 10:04:45 AM
WINT, Amazing news just out:
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
2025-07-24 09:00 ET - News Release
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy
Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB
WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced it has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit (“ELOC”) and bolster its BNB cryptocurrency treasury strategy. The company also entered into an additional $20 million stock purchase agreement with Build and Build Corp. Ninety-nine percent of the proceeds from the ELOC and Build and Build Corp will be allocated to acquiring BNB cryptocurrency. The ELOC may not be used until the Company has obtained stockholder approval to increase its authorized shares of common stock.
"We are excited to incorporate these new facilities to enable our future BNB acquisitions as part of our BNB treasury strategy," stated Jed Latkin, CEO of Windtree. "Pending stockholder approval, the opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy."
Establishing the ELOC reflects Windtree’s strategy to diversify its treasury assets and leverage the potential of blockchain-based digital currencies. The Company remains committed to prudent financial management while exploring innovative avenues to drive stockholder value.
“Windtree’s strategy to integrate BNB into its treasury reflects a forward-thinking approach to value creation,” said Patrick Horsman, CFA, Director of Build and Build Corp. “The ELOC provides the flexibility and scale needed to execute on this digital asset treasury vision.”
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
2025-07-24 09:00 ET - News Release
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy
Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB
WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced it has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit (“ELOC”) and bolster its BNB cryptocurrency treasury strategy. The company also entered into an additional $20 million stock purchase agreement with Build and Build Corp. Ninety-nine percent of the proceeds from the ELOC and Build and Build Corp will be allocated to acquiring BNB cryptocurrency. The ELOC may not be used until the Company has obtained stockholder approval to increase its authorized shares of common stock.
"We are excited to incorporate these new facilities to enable our future BNB acquisitions as part of our BNB treasury strategy," stated Jed Latkin, CEO of Windtree. "Pending stockholder approval, the opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy."
Establishing the ELOC reflects Windtree’s strategy to diversify its treasury assets and leverage the potential of blockchain-based digital currencies. The Company remains committed to prudent financial management while exploring innovative avenues to drive stockholder value.
“Windtree’s strategy to integrate BNB into its treasury reflects a forward-thinking approach to value creation,” said Patrick Horsman, CFA, Director of Build and Build Corp. “The ELOC provides the flexibility and scale needed to execute on this digital asset treasury vision.”
Recent WINT News
- Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates • GlobeNewswire Inc. • 12/23/2025 02:00:00 PM
- Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space • GlobeNewswire Inc. • 12/03/2025 02:00:00 PM
- Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee • GlobeNewswire Inc. • 11/17/2025 02:00:00 PM
- Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate • GlobeNewswire Inc. • 11/14/2025 02:00:00 PM
- Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company • GlobeNewswire Inc. • 11/13/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 06:27:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/02/2025 09:16:05 PM
- Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting • GlobeNewswire Inc. • 09/02/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 04:15:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2025 09:29:07 PM
- Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 • GlobeNewswire Inc. • 08/11/2025 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/08/2025 09:08:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:54:53 PM
- Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients • GlobeNewswire Inc. • 08/05/2025 01:00:00 PM
- Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption • GlobeNewswire Inc. • 07/29/2025 01:01:29 PM
- Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy • GlobeNewswire Inc. • 07/24/2025 01:00:00 PM
- Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services • GlobeNewswire Inc. • 07/22/2025 01:00:00 PM
- Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions • GlobeNewswire Inc. • 07/16/2025 01:22:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/14/2025 04:15:09 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/10/2025 01:23:56 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/07/2025 08:55:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 06:26:36 PM
- Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure • GlobeNewswire Inc. • 07/02/2025 01:00:00 PM
- Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis • GlobeNewswire Inc. • 06/30/2025 01:00:00 PM
- Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel • GlobeNewswire Inc. • 06/26/2025 08:05:00 PM
